The Correlation of BRAF V600E Expressions with Histopathological Variant and Lymphocyte Infiltration in Papillary Thyroid Carcinoma

Abstract

Background
Papillary thyroid carcinoma is the most common endocrine gland malignancy that has the highest incidence rate of 60-80%. In papillary
thyroid carcinoma BRAF V600E mutation plays an important role in carcinogenesis. BRAF V600E is a RAS-regulated-serine-threonine
kinase and activator of the MAPK pathway cascade that functions to regulate cell proliferation, differentiation and survival. BRAF
V600E mutations in PTC is associated with a high incidence of recurrence and reduced survival. The purpose of this study is to look
at the relationship of BRAF V600E expression with histopathological variants and lymphocyte infiltration in PTC.
Methods
This research was a retrospective observational cross sectional study with 40 cases of papillary thyroid carcinoma which were
diagnosed in 4 Pathology Anatomy Laboratory in West Sumatera. Samples were obtained from paraffin blocks of tissue from surgery
and were reevaluated for histopathological variant and lymphocyte infiltration. Expression of BRAF V600E in tumor cell were analyzed
using immunohistochemistry staining. Bivariate statistical analysis of Chi-Square were used and p value <0,05 were considered
significance.
Results
Positive BRAF V600E expression was found in 24 case (60%). Positive BRAF V600E expression was mostly found in classic PTC
(50%). Papillary thyroid carcinoma with lymphocyte infiltration mostly found with negative BRAF V600E expression (79.2%). Statistical
analysis showed no significant correlation between BRAF V600E with histopathological variant (p=0.74) and no significance
correlation between BRAF V600E expression with lymphocyte infiltration (p=0.12).
Conclusion
The conclusion is BRAF V600E expression has no correlation with histological variants in papillary thyroid carcinoma and no significant
correlation of BRAF V600E expression with lymphocyte infiltration.